Pelrinone Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414834

CAS#: 94386-65-9 (free base)

Description: Pelrinone Free Base, a cardiotonic drug, is a phosphodiesterase III inhibitor that was studied in clinical trials phase II for the treatment of patients with heart failure.

Chemical Structure

img
Pelrinone Free Base
CAS# 94386-65-9 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 414834
Name: Pelrinone Free Base
CAS#: 94386-65-9 (free base)
Chemical Formula: C12H11N5O
Exact Mass: 241.10
Molecular Weight: 241.250
Elemental Analysis: C, 59.74; H, 4.60; N, 29.03; O, 6.63

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 94386-65-9 (free base)   89232-84-8 (HCl)    

Synonym: Pelrinone Free Base; Pelrinona; Pelrinonum

IUPAC/Chemical Name: 5-Pyrimidinecarbonitrile, 1,4-dihydro-2-methyl-4-oxo-6-((3-pyridinylmethyl)amino)-

InChi Key: NZXHFDXOCVIYLO-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H11N5O/c1-8-16-11(10(5-13)12(18)17-8)15-7-9-3-2-4-14-6-9/h2-4,6H,7H2,1H3,(H2,15,16,17,18)

SMILES Code: N#CC1=C(NCC2=CC=CN=C2)NC(C)=NC1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 241.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Scatina JA, Hicks DR, Kraml M, Cayen MN. Metabolic disposition and pharmacokinetics of pelrinone, a new cardiotonic drug, in laboratory animals and man. Eur J Drug Metab Pharmacokinet. 1990 Jan-Mar;15(1):37-48. doi: 10.1007/BF03190126. PMID: 2384116.

2: Hajdu J, Adams G, Lee HK. Preformulation study of pelrinone hydrochloride. J Pharm Sci. 1988 Nov;77(11):921-5. doi: 10.1002/jps.2600771104. PMID: 3225750.

3: Patelunas DM, Carmint WJ, Willis JZ, Colatsky TJ, Fenichel RL. Comparative antithrombotic activities of the phosphodiesterase inhibitors pelrinone (AY-26,768), AY-31,390 and milrinone. Thromb Res. 1991 Jun 1;62(5):389-400. doi: 10.1016/0049-3848(91)90012-l. PMID: 1896959.

4: Kitzen JM, McCallum JD, Harvey C, Morin ME. Antithrombotic activity of the phosphodiesterase III inhibitor pelrinone in a canine model of coronary artery thrombosis: enhancement of efficacy with concurrent alpha 2-adrenergic antagonism. J Cardiovasc Pharmacol. 1991 Dec;18(6):777-90. doi: 10.1097/00005344-199112000-00001. PMID: 1725888.

5: Bagli J, Bogri T, Palameta B, Rakhit S, Peseckis S, McQuillan J, Lee DK. Chemistry and positive inotropic effect of pelrinone and related derivatives. A novel class of 2-methylpyrimidones as inotropic agents. J Med Chem. 1988 Apr;31(4):814-23. doi: 10.1021/jm00399a023. PMID: 2832602.

6: Kitzen JM, McCallum JD, Pirozzi CT, Colatsky TJ. Potentiation of phosphodiesterase inhibitor antithrombotic activity with alpha-2 adrenergic blockade. Life Sci. 1991;48(7):PL31-5. doi: 10.1016/0024-3205(91)90548-p. PMID: 1671293.

7: Greenberg SS, Diecke FP, Cantor E, Peevy K, Tanaka TP. Inhibition of sympathetic neurotransmitter release by modulators of cyclic GMP in canine vascular smooth muscle. Eur J Pharmacol. 1990 Oct 23;187(3):409-23. doi: 10.1016/0014-2999(90)90368-g. PMID: 1981554.